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Abstract 
 
Background 
Our objective was to describe S. aureus bacteriuria (SABU) at a population-based level 
and determine patient characteristics associated with S. aureus bacteremia (SAB). 
Methods 
A retrospective study was performed using electronic databases. All urine cultures 
positive for S. aureus between 2010-2013 within the Calgary Health Zone were included. 
Patient characteristics were compared among patients with and without SAB and risk 
factors identified using multiple logistic regression modelling.   
Results  
A total of 2540 urine cultures positive for S. aureus from 2054 patients were analyzed. 
The incidence of SABU was greatest amongst geriatric males with multiple 
comorbidities. 175 (6.9%) of the cohort had SAB. Those with concurrent SAB were more 
likely to be hospitalized, male, have a recent urinary procedure, have pure S. aureus 
culture in urine and have laboratory findings suggesting systemic infection. In-hospital 
mortality in patients with SABU and SABU + SAB was 9.2% and 17.5%, respectively. 
Patients with SABU detected ≥48 hours before SAB had the highest risk of death. 
Conclusions 
Less than 7% of patients with SABU have or will develop SAB. Characteristics 
associated with SABU were identified that established higher risk for systemic infection. 
Investigating SABU patients with these characteristics for systemic infection is warranted 
since a delay in diagnosis is associated with increased mortality.  
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INTRODUCTION 
 
Staphylococcus aureus 
Staphylococcus aureus is a common pathogen of worldwide importance. It is a        
Gram-positive coccus that can colonize the skin and mucosa of animals and humans. It 
causes a wide range of infections, from benign skin infections such as folliculitis to deep-
seated infections such as endocarditis and osteomyelitis. It is also a critical pathogen in 
nosocomial infections, being the most prevalent microorganism detected in sterile sites 
among hospitalized inpatients (18.7%).1  
 
Invasive S. aureus infections are rising. For example, the average annual incidence of S. 
aureus invasive infections in Calgary between 2012 - 2014 was 26.3 cases per 100,000 
people compared to 19.7 cases per 100,000 people in 2000-2006.1,2 Infections due to 
methicillin-resistant Staphylococcus aureus (MRSA) are also increasing, with national 
MRSA infections from 2012 – 2015 increasing annually by approximately 5%.3 
Increasing S. aureus infections are a major concern for several reasons. First, invasive S. 
aureus infections can be lethal, with thirty-day mortality at approximately 25% among 
individuals with S. aureus bacteremia.1,2,4,5 Second, the costs of treating S. aureus 
infections can be substantial. For instance, 6 month median costs per methicillin-sensitive 
Staphylococcus aureus (MSSA) and MRSA infection, including bacteremia, are 
approximately US $15,923 and US $34,657, respectively.6 
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So why is mortality so high among invasive S. aureus infections? The answer lies in S. 
aureus’ many virulence factors that include the production of numerous adhesins, toxins 
and coagulases. S. aureus has over 20 adhesin genes and over 30 toxin genes.7-10 
Compare this to other Staphylococci, such as coagulase negative Staphylococcus, that 
produce less than ten adhesin genes and no toxin or coagulase genes. S. aureus is 
considered a “sticky” bacterium through the production of numerous adhesions. These 
adhesins allow S. aureus to colonize skin and foreign devices such as urinary 
catheters.11,12 Up-regulation of adhesins is also thought to allow S. aureus to migrate from 
the skin into the bloodstream, attach to endothelial cells within the bloodstream and 
subsequently invade into host tissues.11 Other S. aureus virulence factors include toxins 
such as proteases, hemolysins and leukotoxins which can lead to surrounding tissue 
destruction and destruction of white blood cells that help it evade the immune system.13 
Lastly, the production of coagulases (staphylocoagulase and von Willebrand factor) allow 
S. aureus to form fibrin clots which helps with abscess formation, immune system 
evasion, and formation of biofilms.13 In S. aureus bacteriuria, abnormal tissue or foreign 
devices (i.e. urinary catheter) allow S. aureus to attach and form biofilms, creating an 
environment for S. aureus to thrive in the bladder. Eventually, the presence of S. aureus 
in the bladder may lead to urinary tract inflammation followed by translocation into the 
bloodstream.  
 
S. aureus is a critical player in the era of multidrug resistant pathogens. By having many 
capabilities to share genetic material with itself and other Staphylococcal species, S. 
aureus has evolved into an antimicrobial resistant capable pathogen. When penicillin was 
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first introduced in the 1940s, S. aureus quickly became drug resistant, through the 
production of penicillinase, to the point that the majority of clinically isolated S. aureus 
are resistant to penicillin. As new drugs were developed to counteract S. aureus 
resistance, S. aureus continued to evolve to increase its resistance profile. Since the 
1950s, a S. aureus resistant to many antibiotics, called methicillin-resistant 
Staphylococcus aureus (MRSA), has emerged. At present day, MRSA is now the 
dominant S. aureus strain circulating in some US centers (60%) and, in a Canadian city 
like Calgary, represents 22.6% of S. aureus isolated from blood cultures collected from 
the Calgary community facilities and emergency rooms.14,15 MRSA is a critical pathogen 
because it not only causes invasive disease but the main drug developed to help combat it 
(i.e. vancomycin) is inferior and more toxic than drugs, such as cloxacillin, that are used 
to treat its less resistant counterpart, methicillin-sensitive Staphyloccocus aureus 
(MSSA).16 Moreover, MRSA infections are associated with increased mortality compared 
to MSSA infections. For instance, thirty-day mortality rates for MSSA and MRSA 
bacteremia in Calgary was 21.2% and 31.0%, respectively.2 
 
S. aureus infections usually occur from S. aureus residing on an individual’s skin flora. S. 
aureus can be part of normal skin flora with approximately 20 - 27% of the normal 
population having the microorganism residing in the anterior nares at any given time.17 
Approximately 60% of the population carries S. aureus intermittently, 20% persistently, 
and 20% never.18 Other less common sites of colonization include the mouth, intestine, 
vagina, intertriginous skin folds, the axillae, the groin and the perineum. Different 
activities can influence an individual’s risk of acquiring S. aureus and MRSA. Nasal 
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carriage of S. aureus, for instance, increases with healthcare exposure, diabetes, dialysis, 
drug addiction and human immunodeficiency virus infection (HIV).18 Sites of S. aureus 
colonization also differ based on certain risk factors. An evaluation of S. aureus carriage 
among patients presenting to a community based sexually transmitted infection (STI) 
clinic found a preferential carriage for the throat (41.5%) compared to the anterior nares 
(31.7%) [p = 0.01].19 Increased risk of throat carriage was associated with >6 
heterosexual sexual contacts in the last 6 months, practicing oral sex and trimming of 
pubic hair.19 Although the majority of people with S. aureus colonization do not develop 
symptomatic disease, they are at increased risk of S. aureus infection, as evidenced by the 
fact that 82.2% of patients with S. aureus bacteremia exhibit prior/current colonization 
with the same strain.20,21,22 In S. aureus bacteriuria (SABU), nasal colonization was 
detected in 75% of patients in one study.23 Other sites of S. aureus colonization, 
particularly the perineum, have yet to be explored among SABU individuals.  
 
S. aureus Bacteriuria (SABU) 
Despite being a common, sometimes life-threatening and often multidrug resistant 
pathogen, S. aureus is not typically associated with urinary tract infections. The most 
recent literature suggests that S. aureus represents only 0.2 to 4% of positive urine 
samples and 1% of uncomplicated urinary tract infections (UTIs).24-27 Urinary tract 
infections generally occur when uropathogens from the gut colonize the urethra, usually 
via contamination, and migrate upwards into the bladder through the use of motility 
structures such as flagella and pili.27 Most uropathogens have unique characteristics that 
allow them to flourish in the bladder. These include adhesins and pili that can adhere to 
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the uroepithelium, obtain nutrients from host cells through specific protease and toxin 
production, and evade the immune system present within the urinary tract by invading 
into the cytoplasm of uroepithelial cells.27 If left untreated, urinary pathogens can 
eventually ascend to the kidneys, cross the tubular epithelial barrier, and enter the 
bloodstream.28 Unlike common uropathogens such as E. coli or K. pneumoniae, S. aureus 
lacks many of these characteristics to reach and thrive within the bladder. In simpler 
terms, S. aureus “sticks”, but doesn’t “swim.”   
 
The prevalence of S. aureus increases in complicated UTIs (3%), defined as those 
associated with urinary catheterization or urinary tract abnormalities.27 As mentioned 
previously, the presence of a urinary catheter allows S. aureus to adhere and colonize the 
catheter inside the bladder which can subsequently lead to S. aureus infection. In fact, 
urinary catheterization appears to be the most common cause of SABU, impacting over 
60% of SABU individuals in many studies.23,25,29,30 Several studies have also implicated 
urinary catheters as a site of MRSA acquisition and colonization during MRSA 
outbreaks.31,32 Other associations with SABU include urinary tract procedures such as 
cystoscopy,23,25,26,29,30,33 urinary tract abnormalities and obstruction,25,29 nursing home 
resident,34 healthcare exposure,25,29,33,34 male gender,25 and older age.26,33,35-37 
 
Interestingly, high rates of SABU have been reported among asymp tomatic pregnant 
women in certain African countries. In studies on asymptomatic pregnant females in 
Nigeria, Ethiopia, Ghana, Sudan, and Uganda, S. aureus was detected in 6.2 – 45.9% of 
positive isolates.38-46 It is thought that female genital mutilation (FGM) might be the 
 6 
reason behind higher SABU rates in these settings.47 The abnormal perineal tissue caused 
by FGM may provide S. aureus with better affinity to colonize the genitourethral area, 
thereby leading to SABU in improperly collected samples. However, the prevalence of 
female genital mutilation among women aged 15 – 49 is <10% in countries such as 
Ghana and Uganda which makes this explanation less likely.48 Regardless of the etiology, 
SABU in pregnant females should not be taken lightly since S. aureus is the most 
common cause of neonatal sepsis within these countries.49-53 The association between 
SABU and neonatal sepsis due to S. aureus within these settings remain unclear and 
further studies are warranted. 
 
S. aureus Bacteremia in Individuals with S. aureus Bacteriuria 
While SABU often represents urinary colonization, contamination or an uncommon 
cystitis, a small portion may be a harbinger of deep-seated pyogenic infections and S. 
aureus bacteremia (SAB). Unfortunately, the literature on the development of SAB in 
individuals with SABU is scarce, with only 9 studies found during a literature review 
conducted by this author.23-26,29,35,37,54,55 Among the studies, the definition of SABU 
varied, with the most common being S. aureus >105 CFU/mL.23,25,29 Regardless, all the 
studies have suggested that SABU is a potential marker of S. aureus bacteremia, with 
12.0 - 48.8% of SABU individuals having or developing SAB.23-26,29,35,37,54,55 Most SAB 
cases occurred within 48 hours of SABU detection. However, a not insignificant number 
of bacteremic cases (27.0% - 38.0%) and non-bacteremic invasive S. aureus disease 
(41.1% - 66.7%) were detected after 48 hours of urine collection, highlighting the 
potential need for follow up investigations when SABU is detected.23,24,37 
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Risk factors associated with SAB in SABU vary among published cohorts, emphasizing 
the need for population-based studies such as ours. Potential risk factors associated with 
SAB in SABU are male gender,55 urinary catheterization,23 gross hematuria,23 and 
inpatient status.24 A review examining SABU’s association with deeper-seated S. aureus 
infections, including SAB, identified anti-Staphylococcal antibiotics, the absence of UTI 
symptoms, inpatient status and MRSA as risk factors for invasive S. aureus disease.24 
Those less likely to have concurrent SAB during SABU included patients with urinary 
tract abnormalities or recent intervention,55 and pyuria.55 However, all studies examining 
SAB in SABU have had small sample sizes and weak external validity. Indeed, the largest 
study included only 41 individuals with SAB24 while others had <20. Studies generally 
were conducted at single centers and most assessed selected populations such as males in 
veteran hospitals or inpatients.  
 
 Associated infections in SABU + SAB varies in the medical literature. Many studies 
report the underlying diagnosis as being isolated urinary tract infection, though many do 
not provide proper definitions. In one study, most SABU + SAB cases occurred one to 
three days after a urinary tract procedure (cystoscopy, transurethral prostatic resection or 
urinary catheterization).25 In the largest study which examined for invasive disease over 
the course of 12 months from SABU detection, the most common associated site of 
infection in patients with SABU + SAB was bacteremia of unclear etiology (41.9%), 
followed by pneumonia (13.3%), endocarditis (9.3%) and osteomyelitis (7.0%).24 In 
another smaller study, the most common associated infection for bacteremia was wound 
infection (27.3%), endocarditis (22.7%), UTI (22.7%), and pneumonia (9.1%).37 
 8 
S. aureus Bacteriuria in Individuals with S. aureus Bacteremia 
Many studies have examined SABU in individuals with SAB. Within those studies, 
SABU occurred in approximately 7 - 34% of individuals with SAB.56 Comparatively, 
SABU was present in 8.1% of SAB cases in the Calgary Health Zone over 2012 - 2014 
[unpublished data]. In a recent meta-analysis examining SABU in individuals with SAB, 
individuals with SABU + SAB had increased mortality (OR 1.97, 95% CI 1.28 – 2.88) 
and more persistent bacteremia than individuals with SAB alone.56 These findings are 
thought to be due to SABU + SAB individuals having a more serious invasive infection, 
such as endocarditis with septic emboli and bone/joint infections.56 
 
Study Aims 
In this study, we aimed to describe the incidence and outcomes of SABU from a large, 
diverse Canadian population (over 1.4 million individuals) and to identify population-
based risk factors associated with SAB and deeper-seated S. aureus infection amongst 
those with SABU. We hypothesize that S. aureus is an uncommon urinary tract isolate in 
general populations and represents a marker of invasive S. aureus infection in only 
specific populations with SABU. The identification of those specific individual 
characteristics and clinical presentations that associate with invasive disease can be used 
to help clinicians identify individuals at risk.  
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METHODS 
 
Data Collection  
All urine culture results reported as positive for S. aureus between January 1, 2010, to 
December 31, 2013, from Calgary Laboratory Services (CLS) were examined. CLS is a 
centralized laboratory for the Calgary Health Zone (CHZ) that covers all 43 health care 
centers, including 12 acute care sites, and serves over 1.4 million people.58,59 
Cultures were reported as positive for S. aureus when the urine culture grew pure S. 
aureus at 106 – 107 colony forming units (CFU)/L or >107 CFU/L with no more than 1 
other organism present. S. aureus from non-routine urine cultures (defined below under 
subheading “definitions”) were reported as positive if the S. aureus colony count was 
>104 CFU/L with no more than one other organism present. The presence of periurethral 
flora, defined as organisms resembling periurethral flora that were <107 CFU/L in the 
presence of a uropathogen 107 CFU/L was excluded. Only individuals ≥18 years of age 
were included. Urine cultures within 3 months of each other and of the same S. aureus 
antibiogram were excluded as these were presumed to represent the original infection.  
 
Data on individual’s demographics, microbiologic and laboratory data, underlying 
comorbidities, urinary procedures and outcomes were extracted from ICD-9 codes using 
Data Integration, Management and Reporting (DIMR) and the Alberta Discharge Abstract 
Database (DAD).60 Population data was obtained from the Alberta Health Services 
Interactive Health Data Application.61 
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Laboratory data collected within 48 hours of positive urine culture results were included 
in the analysis. This included urinalysis, complete blood counts (CBCs), serum creatinine 
and C-reactive protein (CRP), where available. If laboratory data was repeated within 48 
hours, only values closest to the time of urine culture were included. Blood cultures and 
cultures from sterile fluid, tissue, cerebrospinal fluid (CSF), hardware, catheter tips, and 
deep abscesses that were positive for S. aureus growth were included if they occurred 
within 3 months of any SABU. Procedures related to the urinary tract, including 
cystoscopy and surgery of the urinary tract, were also reported if they occurred within 
four weeks before urine culture. Sources of seeding in patients with SABU + SAB and 
SABU + deeper-seated S. aureus infection were determined through electronic chart 
review. This study received ethical approval from the Conjoint Health Regional Ethics 
Board of the University of Calgary (REB 14-1488).   
 
Definitions 
Non-routine urine culture is defined as any urine culture collected from a suprapubic 
bladder aspirate, nephrostomy tube, urinary stent, ureterosigmoidostomy, ureter, 
cystoscopy, kidney, or a mitroffanoff fluid. 
 
Death was defined as all cause mortality during hospitalization – and recorded for only 
those who were hospitalized.  
 
Recurrent or persistent SABU was defined as SABU occurring ≥3 months apart, or ≤3 
months with different antibiograms.  
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Outpatients included those who had urine samples taken in community laboratories, 
urgent and long-term care facilities and emergency rooms. Patients with SABU who had 
their urine culture collected in an outpatient setting but were subsequently admitted were 
labelled as an outpatient in our study. Inpatients were defined as patients who had their 
urine culture collected >48 hours after hospital admission 
 
Cardiovascular disease was defined as any of the following: myocardial infarction, 
cardiac pacemaker, aortic stenosis, arterial thrombosis, abdominal aortic aneurysm, 
coronary artery disease, peripheral vascular disease, ischemic heart disease and atrial 
fibrillation.  
 
Neurologic disorder was defined as any disorder affecting the neurological system, 
including but not limited to Parkinson’s disease, multiple sclerosis, paraplegia, 
hydrocephalus, spinal cord injury, cardiovascular accident (CVA), epilepsy, dementia, 
and amyotrophic lateral sclerosis (ALS).  
 
Respiratory disease was defined as any of the following: pneumonia, sleep apnea and 
chronic obstructive pulmonary disease (COPD).  
 
Urological disorder was defined as any disorder affecting the genito-urethral system, 
including but not limited to urinary retention, prostatitis, an artificial opening of the 
urinary tract, hypoplasia of the penis, urethral stricture, ureter stricture, urinary foreign 
body and urinary incontinence. 
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Immunosuppression was defined as any transplant recipient, chronic steroid use, 
hematological malignancy and patients with HIV. Chronic steroid use was based on ICD-
9 coding.  
 
The presence of urine leukocytes was defined as a positive leukocyte esterase urine 
dipstick.  
 
Statistical Analysis 
Characteristics between SABU individuals with or without SAB and with or without 
deeper-seated S. aureus infection were compared. A subgroup analysis for outpatients, 
including emergency room visits, and for individuals with or without a urinary catheter 
was conducted. Risk factors associated with death during hospital admission were also 
analyzed. Associations between predictive variables and aforementioned outcomes were 
independently evaluated using chi-square test or Fisher’s exact test for discrete variables 
and independent two-sample t-test or Mann-Whitney U-test for continuous variables. 
Variables that had a p-value <0.10 were included in a stepwise multiple logistic 
regression model. Independent variables with p<0.05 after stepwise regression were 
included in the final multivariate logistic regression model and associations were reported 
as odds ratios (OR) with 95% confidence intervals (CI). Laboratory data were excluded 
from the multivariate regression model due to incomplete data (not all individuals with 
SABU had laboratory investigations). Instead, laboratory outcomes were individually 
adjusted using the final multivariate logistic regression model. All statistical analysis was 
done using STATA 14.0 (Stata Corp., College Station, TX, USA). 
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Systematic Review and Meta-Analysis 
A systematic review using a predetermined protocol and in accordance with PRISMA 
standardized reporting guidelines was conducted.62 Investigator WS searched electronic 
databases from inception to Janurary 6, 2018, including Google Scholar, Pubmed, Web of 
Science, EMBASE and MEDLINE. No language restrictions were applied. Conference 
proceedings from the Annual Meetings of the Infectious Diseases Society of America 
were searched from 2003 - onwards for relevant abstracts. The references of relevant 
articles were also searched. The search strategy combined the names and alternate names 
of “Staphylococcus aureus”, “urinary tract infection” (or “bacteriuria”) and “bacteremia” 
using the Boolean operator AND to map (search by keyword) and explode (search by 
subject heading where appropriate). Alternative names of Staphylococcus aureus, urinary 
tract infection and bacteremia were combined using the Boolean operator OR (see 
Appendix A). Our search was broad in order to capture all relevant publications. 
 
Articles were included in the systematic review if they were articles presenting 
independent research related to S. aureus bacteremia in individuals with S. aureus 
bacteriuria. Case reports were excluded. Studies that examined S. aureus bacteriuria in 
individuals with S. aureus bacteremia were excluded.  
 
Systematic Review and Meta-Analysis: Data Extraction and Quality Assessment 
Data extracted in the systematic review included study characteristics (publication year, 
geographic location, sample size), individual characteristics (age, gender, comorbidities, 
symptoms), laboratory characteristics (MRSA, pyuria, colony count, mixed culture), 
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urinary procedures and outcomes (SAB, invasive S. aureus infection, death). Study 
quality was assessed using the Newcastle-Ottawa scale for assessing the quality of cohort 
studies.63 This scale includes assessments of the exposed cohort, non-exposed cohort, 
ascertainment of exposure, assessment of outcomes, comparability of cohorts, and 
adequacy and length of follow-up.  
 
For the meta-analysis, we sought to determine whether urinary catheters in SABU 
individuals increases the risk for developing SAB. For our secondary outcome, we pooled 
other characteristics found to be associated with SAB among SABU individuals. These 
included urinary obstruction, presence of urinary tract infection symptoms, pyuria, 
gender, inpatient status and diabetes. Pooled odds ratios were visually demonstrated using 
forest plots and heterogeneity among studies was assessed using the I2 and Cochran Q 
statistics. Odds ratios of development of SAB in individuals with SABU who have 
urinary catheters were also pooled using random effects models, with individuals without 
urinary catheters as the reference group. As a sensitivity analysis for all pooled estimates, 
fixed effect models were generated to assess the robustness of the findings. Finally, small 
study effects, potentially indicative of publication bias, was assessed visually through a 
funnel plot and tested for using Begg and Mazumdar’s rank correlation test for 
asymmetry.64 A significant statistical test (p<0.05) or observed funnel plot asymmetry 
suggests small study effects that may potentially be caused by publication bias. All 
analyses were conducted using STATA 14.0 (Stata Corp., College Station, TX, USA)
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RESULTS 
 
Epidemiology of SABU 
Between 1/1/2010-12/31/2013, 875,587 urine cultures with significant growth were 
collected. Of those, 3739 (0.4%) were reported positive for S. aureus. A total of 1199 
cultures were excluded from analysis based on our exclusion criteria, leaving 2540 
cultures from 2054 patients for analysis. This corresponded to a rate of 174/100,000 in the 
general population of the CHZ. Of the 1199 excluded cultures, 137 were from 100 
individuals aged <18 years old, none of whom developed SAB. The other 1062 cultures 
were excluded for being within 3 months of each other and of the same S. aureus 
antibiogram. SAB occurred in 6.9% (175) of patients with SABU. 
 
SABU cases as a proportion of the general population declined 14% from 2010 - 2013 
(p=0.04, linear regression), whereas the number of SABU + SAB cases have remained 
relatively constant (p=0.74) (Figure 1). The presence of a urinary catheter at the time of 
urine collection also declined each year (p<0.001) (Figure 2). SABU was equally 
represented between genders (51.3% male). However, when comparing to the population 
of the CHZ, SABU occurred at a higher rate among males and disproportionally among 
the older population, reaching a peak incidence of 552/10,000 among males aged ≥85 
years (Figure 3). For reference, the population of the Calgary Health Zone, by age cohort, 
is provided in Figure 4. Compared to SABU, the rate of SABU + SAB also occurred 
among slightly younger age cohorts (Figure 5).  
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Figure 1        Rate of SABU and SABU + SAB cases within the Calgary Health Zone  
                       per year. 
 
 
 
 
 
Figure 2        Percentage of individuals with a urinary catheter at time of urine collection  
                       within the Calgary Health Zone per year. Decrease in SABU for patients        
                       with and without urinary catheter declined by 10% and 39%, respectively    
                       (p<0.001).  
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Figure 3        Rate of SABU within the Calgary Health Zone, by age cohort, averaged  
                       from 2010 – 2013. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4        Population of Calgary Health Zone, by age cohort, averaged from 2010- 
                       2013. 
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Figure 5         Rate of SAB in individuals with SABU within the Calgary Health Zone, by     
                        age cohort, averaged from 2010 – 2013. 
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Comorbidities were more prevalent among individuals with SABU or SABU + SAB than 
the Calgary Health Zone population (Table 1). In particular, diabetes in SABU 
individuals was more than double the prevalence among the CHZ general population and 
higher yet in individuals with SABU + SAB. Dementia in SABU individuals was more 
prevalent than the Calgary Health Zone population but lower than the SABU + SAB 
populations. Overall, more comorbidities were present in SABU individuals compared to 
SABU + SAB individuals or the general Calgary Health Zone population.  
Most urine cultures had pure growth of S. aureus. S. aureus at ≥108, 107 - 108, 106 - 107 
colony forming units per liter (CFU/L) was detected in 53.0%, 33.2%, 13.4% of urine 
cultures, respectively. Colony count was not associated with increased risk of SAB. S. 
aureus was inappropriately reported as positive in 9 samples. This included 2 samples 
(0.08%) which were reported as positive for S. aureus when S. aureus was <106 CFU/L 
and 7 samples (0.3%) which were reported as positive for S. aureus when S. aureus was 
106 – 107 CFU/L in the presence of other organisms. By the protocol used in our 
laboratory, these samples should not have been reported as S. aureus. None of the 11 
samples were from individuals who developed SAB. Reasons for reporting these samples 
include human error or by request from a medical microbiologist.   
 
Urinary catheters accounted for 18.7% of our urine culture sources. An in/out catheter 
accounted for 2.3%. There were a total of 22 (0.87%) non-urine sources (17 nephrostomy 
tubes, 3 cystoscopies and 2 suprapubic catheters). In the 2540 urine culture specimens, 
37.0% had the combination of pure S. aureus and a colony count ≥108 CFU/L.  
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Table 1         Prevalence of comorbidities between Calgary Health Zone general  
                      population and individuals with SABU. 
 
Comorbidity Calgary 
Health Zone 
(% )61 
SABU (% )  
P-value 
SABU + SAB 
(% ) 
 
P-value* 
Diabetes 5.03 10.57 <0.001 18.86 <0.001 
Multiple sclerosis 0.24 1.10 <0.001 1.14 <0.001 
Cirrhosis 0.18 0.59 <0.001 2.29 <0.001 
COPD 1.89 4.10 <0.001 4.00 <0.001 
Dementia 1.80 6.72 <0.001 2.29 <0.001 
ESRD 0.09 0.08 0.078 0.57 <0.001 
Parkinson’s  0.11 0.89 <0.001 0 <0.001 
Epilepsy 1.32 0.30 <0.001 1.71 <0.001 
Ischemic heart 
disease 
2.99 1.73 <0.001 2.29 <0.001 
Two or more 
comorbidities** 
7.25 13.07 <0.001 12.00 <0.001 
Three or more 
comorbidities** 
2.05 4.14 <0.001 2.86 <0.001 
Four or more 
comorbidities** 
0.48 0.72 <0.001 0 <0.001 
*P-value based on SABU + SAB compared to prevalence in Calgary Health Zone  
**Comorbidities based on Parkinson’s disease, end stage renal disease (ESRD), asthma, congestive heart 
failure, chronic obstructive lung disease (COPD), hypertension , ischemic heart disease, multiple sclerosis, 
diabetes, inflammatory bowel disease. Number of comorbidities  examined was limited by the data available 
in the AHS interactive health data application.61 
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Periurethral flora, which was excluded in our study, was present in 7.5% of included 
SABU cultures. The most common concurrent organisms detected in mixed urine cultures 
was Enterococcus faecalis at 28%. MRSA was present in 23.1% of SABU specimens and 
is similar to the overall prevalence of MRSA among S. aureus blood culture isolates in 
community individuals within the Calgary Health Zone.14 
 
S. aureus Bacteremia and its Association with SABU 
Characteristics of individuals with SABU and SABU + SAB are displayed in Table 2. 
Compared to SABU, individuals with SABU + SAB were more likely to be younger, 
male, an inpatient, have a recent urinary procedure and have pure S. aureus culture.  
Individuals with SABU + SAB also had higher prevalence of liver cirrhosis, malignancy, 
diabetes, kidney disease and immunosuppression. SABU individuals were more likely to 
be from a nursing home and have dementia, MRSA, and recurrent or persistent SABU. 
 
Laboratory characteristics of patients at time of SABU and SABU + SAB are outlined in 
Table 3. Overall, individuals with SABU + SAB had markers suggestive of systemic 
inflammation. Individuals with isolated SABU, in contrast, had higher rates of pyuria, the 
presence of urine leukocytes and positive urine nitrites. Microscopic hematuria was 
similar between groups.   
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Table 2         Demographics and characteristics of individuals with SABU and SABU +  
                      SAB.  
 
 
Variable 
SABU 
N=2365 
SABU+SAB 
N=175 
 
p-value 
Alive 
N=888 
Dead 
N=93 
 
p-value 
Median age (IQR) 74 (30) 65 (23) 0.052 75 (24) 80 (15) <0.001 
Age >65 (%) 62.6 51.4 0.003 66.8 86.0 <0.001 
Male (%) 51.3 69.7 <0.001 60.9 59.1 0.738 
Inpatient (%) 27.3 56.0 <0.001 69.7 88.2 <0.001 
Nursing home resident (%) 16.7 6.9 0.001 5.4 3.2 0.368 
Hospital admission 
(outpatients only) 
19.2 38.3 <0.001 - - - 
ICU admission (%) 0.2 2.9 <0.001 0.90 2.2 0.254 
Recurrent or persistent 
SABU (%) 
18.3 8.6 0.001 17.8 5.4 0.002 
MRSA (%) 23.6 17.1 0.050 27.6 28.0 0.940 
Pure S. aureus cultures* (%) 79.3 84.6 0.096 70.9 66.7 0.389 
Colony count 106 – 107 
CFU/L (%) 
13.3 14.9 0.565 10.6 12.8 0.515 
Colony count 107 – 108 
CFU/L (%) 
33.4 31.4 0.600 30.9 31.9 0.845 
Colony count >108 CFU/L 
(%) 
53.1 52.6 0.895 58.1 54.8 0.550 
Pure S. aureus culture with 
colony count >108 CFU/L 
(%) 
36.9 38.9 0.600 38.1 33.3 0.383 
Presence of catheter (%) 18.5 21.1 0.391 17.0 15.0 0.632 
Recent urinary procedure 
(%) 
1.9 8.0 <0.001 5.41 7.53 0.399 
Liver cirrhosis (%) 0.6 2.3 0.010 1.6 3.2 0.246 
Cardiovascular disease (%) 6.1 7.4 0.464 11.0 24.7 <0.001 
Malignancy (%) 5.0 8.6 0.043 10.5 23.7 <0.001 
Urological malignancy (%) 2.4 2.9 0.683 5.1 10.8 0.023 
Urological disorder (%) 11.5 10.3 0.637 17.1 22.3 0.204 
Diabetes (%) 10.6 18.9 0.001 20.7 25.8 0.254 
Chronic kidney disease (%) 2.6 6.3 0.005 6.0 12.9 0.011 
Neurologic disorder (%) 17.2 12.6 0.117 32.8 36.6 0.460 
Urinary foreign body (%) 1.6 3.4 0.085 2.0 3.2 0.447 
Dementia (%) 6.7 2.3 0.021 13.1 11.8 0.736 
Immunosuppressed (%) 1.3 3.4 0.019 2.5 7.5 0.006 
Positive blood culture - - - 15.5 28.0 0.002 
SAB + SABU within 48 
hours of each other (%) 
- 81.1 - 13.2 21.3 0.031 
SABU 48hrs before SAB** 
(%) 
- 13.7 - 1.7 5.4 0.017 
SAB 48hrs before SABU*** 
(%) 
- 4.6 - 0.6 1.1 0.547 
* Most common concurrent organism detected in mixed cultures was E. faecalis (28%) 
** Median time from SABU to SAB: 409 hours (17.0 days) 
*** Median time from SAB to SABU: 1389 hours (57.9 days) 
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Table 3        Laboratory characteristics of individuals with SABU and SABU + SAB. 
 
Laboratory 
analysis 
Laboratory analysis  SABU SABU + 
SAB 
p-value Alive Dead p-value 
 
 
 
Urine 
findings 
Pure S. aureus 
cultures (%) 
79.3 84.6 0.096 70.9 66.7 0.389 
Urine RBC >10/hpf 
(%) 
39.1 
N=338 
50.0 
N=24 
0.290 38.6 
N=166 
46.2 
N=13 
0.589 
Urine WBC >10/hpf 
(%) 
88.3 
N=332 
58.3 
N=24 
<0.001 84.7 
N=163 
46.2 
N=13 
0.001 
Presence of urine 
leukocytes (%) 
89.0 
N=897 
68.5 
N=73 
<0.001 85.4 
N=425 
83.3 
N=42 
0.717 
Presence of urine 
nitrites (%) 
50.8 
N=890 
34.2 
N=73 
0.007 50.4 
N=425 
50.0 
N=42 
0.965 
 
 
 
 
 
Serum 
findings 
Hgb (g/L), median 118 
N=687 
115 
N=89 
<0.001 114 
N=419 
105 
N=49 
<0.001 
Hgb < 110g/L (%) 34.8  
N=687 
42.7 
N=89 
0.143 43.2 
N=419 
61.2 
N=49 
0.016 
Platelets x 109/L, 
median 
239 
N=685 
190 
N=89 
<0.001 242 
N=418 
155.5 
N=48 
<0.001 
Platelets < 150 x 
109/L (%) 
13.3  
N=685 
40.4 
N=89 
<0.001 17.9 
N=418 
47.9 
N=48 
<0.001 
Platelets >400 x 
109/L (%) 
2.54 
N=685 
2.52 
N=89 
0.080 9.81 
N=418 
6.3 
N=48 
0.425 
Serum WBC x 109/L, 
median  
9 
N=702 
11.2 
N=91 
<0.001 9.8 
N=427 
9.7 
N=47 
0.3796 
Serum WBC >11 x 
109/L (%) 
30.8  
N=702 
50.5 
N=91 
<0.001 37.4 
N=428 
37.5 
N=48 
0.987 
Presence of immature 
neutrophils (%) 
9.9  
N=704 
46.2 
N=93 
<0.001 18.0 
N=428 
27.7 
N=47 
0.108 
CRP [mg/L], median 45.7  
N=26 
261.3 
N=13 
0.012 99.1 
N=28 
23.5 
N=3 
0.9201 
CRP >8mg/L (%) 92.3  
N=26 
92.3 
N=13 
1.00 89.3 
N=28 
100 
N=3 
0.551 
CRP >200mg/L (%) 15.4  
N=26 
76.9 
N=13 
<0.001 35.7 
N=28 
33.3 
N=3 
0.935 
Creatinine, median 86  
N=728 
94 N=98 0.099 88 
N=439 
94.5 
N=50 
0.788 
Creatinine > 
120μmol/L 
31.3  
N=728 
36.4 
N=99 
0.312 34.0 
N=439 
34.7 
N=50 
0.925 
CRP: c-reactive protein. 
WBC: white blood cells. 
Hgb: hemoglobin. 
RBC: red blood cell. 
Hpf: high-power field. 
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Multivariate logistic regression showed that inpatient status, male gender, recent 
urological procedure, pure S. aureus growth, the presence of immature neutrophils, 
thrombocytopenia, leukocytosis and higher CRP levels were significantly associated with 
the presence of SAB in SABU (Table 4). In contrast, dementia, recurrent or persistent  
SABU, age >65 years, urine white blood cell (WBC) >10 cells/hpf and the presence of 
urine nitrites, was significantly associated with isolated SABU.  
 
Associated infections in patients with SABU + SAB are presented in Figure 6. The most 
commonly identified associated infection was from osteomyelitis of the spine or pelvis at 
23% (with many having concomitant epidural abscess), followed by infective 
endocarditis at 11%. Most individuals with infective endocarditis had signs of 
disseminated infection and 26% had seeding of the spine and/or pelvis. No associated 
infection was identified in 44 individuals (25%), although most of these individuals 
(25/44, 56.8%) were labeled as having “urinary tract infection” as their diagnosis from 
physician notes. Because details on urinary symptoms were not accessible by these 
authors, SABU + SAB individuals with a diagnosis of “urinary tract infection” were 
categorized as having “no associated infection identified.” 
 
Invasive S. aureus Infections without Bacteremia and their Association with SABU 
Invasive S. aureus infections without documented SAB occurred in 21 individuals with 
SABU (0.8%). Microbiological samples taken from tissue, deep abscesses, abdominal 
fluid, and synovial fluid made up the majority of sources at 28.6%, 23.8%, 19.0%, and 
14.3%, respectively.  
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Table 4      Multivariate logistic regression analysis of factors associated with SAB in      
                   SABU individuals (N=175/2540). 
 
Predictor Odds ratio*  Adjusted 
p-value 
OR 95%  CI 
Risk factors 
Presence of immature neutrophils   7.3 <0.001 4.3 – 12.1 
Serum platelets <120   5.4 <0.001 3.0 – 9.8 
Serum WBC >15            4.4 <0.001 2.6 – 7.4 
Inpatient 3.6 <0.001 2.6 – 5.0 
Urinary procedure 2.2 0.020 1.1 – 4.3 
Males 2.1 <0.001 1.5 – 3.0 
Pure S. aureus growth 1.6 0.029 1.1 – 2.5 
Protective factors 
Dementia 0.23 0.005 0.08 – 0.63 
Urine WBC>10 cells/hpf       0.20 0.002 0.07 – 0.54 
Presence of urine leukocytes  0.34 <0.001 0.19 – 0.60 
Recurrent or persistent SABU 0.44 0.004 0.26 – 0.77 
Presence of urine nitrites 0.51 0.012 0.31 – 0.87 
Age>65 0.54 <0.001 0.39 – 0.75 
WBC: white blood cells. 
Hpf: high-power field. 
*Adjusted for inpatient status, gender, urinary procedure, dementia, recurrent or persistent SABU, age>65   
  and pure S. aureus culture. 
- Calibration (Pseudo R2)=0.10, discrimination (area under receiver operating characteristic (RoC) curve)=   
   0.74**. 
**Calibration of the final model was assessed using the Hosmer-Lemeshow goodness of fit test and  
    discrimination was assessed using the area under the receiver operator curve.  
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*Other: Septic arthritis, pneumonia, central line infection, intra-abdominal infection,   
             infected skull bone flap, extremity osteomyelitis, septic abortion, infected   
             pericarditis. 
**5 (26%) of individuals with infective endocarditis had confirmed osteomyelitis of  
    spine/pelvis. 
 
Figure 6        Associated infections of SAB in individuals with SABU (N=175).  
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Twenty-four percent of SABU individuals with non-SAB invasive S. aureus infections 
had a skin and soft tissue infection post urinary tract procedure, 19% had septic arthritis, 
19% had an intra-abdominal or pelvic abscess and 14% had  
osteomyelitis of the spine/pelvis (Figure 7).  
 
In Hospital Death 
In hospital death occurred in 93 of 981 hospitalized patients (9.5%). Risk factors for death 
in the multivariate logistic regression model included concurrent SAB + SABU, age >65 
years, cancer, inpatient status, cardiovascular disease, respiratory disease and platelets 
<150x109/L (Table 5). Inpatient status reflects patients who were admitted to hospital 
before collection. Importantly, individuals who had SABU identified ≥48 hours before 
SAB were also more likely to die. Recurrent or persistent SABU and urine WBC >10 
cells/hpf was significantly associated with lower risk of death.  
 
Understanding SABU in the Context of the Community 
SAB occurred in 77/1797 (4.3%) of outpatients (including emergency room patients) with 
SABU. All were subsequently hospitalized or died before hospitalization. Risk factors for 
SAB in outpatients with SABU were similar to that of isolated SABU with several 
differences noted (Table 6). Only individuals with a very elevated WBC count (WBC >15 
x 109/L) had higher risk of SAB. Diabetes and the presence of a urinary catheter were 
associated with SAB in outpatients with SABU.  
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*Other: Fournier’s gangrene, thigh abscess, positive central line blood culture with negative peripheral 
blood cultures. 
 
Figure 7        Associated infections of deep seated S. aureus infection without SAB  
                       (N=21). 
 
 
Table 5         Multivariate logistic regression analysis of risk factors for death in SABU   
                      individuals (N=93/981). 
 
Predictors Odds ratio* Adjusted 
p-value 
OR 95%  CI 
Risk factors  
SABU >48 hours before SAB 8.87 <0.001 2.96 – 26.6 
Platelets < 150 x 109/L  4.16 <0.001 2.05 – 8.47 
Age >65 3.44 <0.001 1.80 – 6.58 
SAB + SABU concurrently 3.14 <0.001 1.73 – 5.69 
Inpatient status 2.75 0.004 1.38 – 5.47 
Cancer 2.54 0.001 1.45 – 4.44 
Cardiovascular disease 1.94 0.020 1.11 – 3.40 
Respiratory disease 1.91 0.021 1.10 – 3.29 
Protective factors  
Urine WBC >10 cells/hpf       0.12 0.006 0.03 – 0.56 
Recurrent or persistent SABU 0.30 0.015 0.11 – 0.79 
*Adjusted for SABU >48 hours before SAB, age >65 years, SAB + SABU concurrently,  
  inpatient status, cancer, cardiovascular disease, respiratory disease, and recurrent or persistent SABU. 
- Calibration (Pseudo R2)=0.13, discrimination (area under RoC curve)= 0.77**. 
**Calibration of the final model was assessed using the Hosmer-Lemeshow goodness of fit test and  
    discrimination was assessed using the area under the receiver operator curve.  
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Table 6      Multivariate logistic regression analysis of risk factors for S. aureus  
                   bacteremia in outpatients with SABU (N=77/1797). 
 
Predictor Odds ratio* Adjusted p-
value 
OR 95%  CI 
Risk factors 
Presence of immature neutrophils   8.84 <0.001 4.24 – 18.46 
Serum platelets <150 x 109/L 5.83 <0.001 2.76 – 12.32 
Serum WBC >15 x 109/L 3.13 0.004 1.44 – 6.78 
Diabetes 3.77 <0.001 1.99 – 7.15 
Presence of a urinary catheter 3.38 <0.001 1.89 – 6.03 
Pure S. aureus culture 2.39 0.026 1.11 – 5.15 
Males 1.80 0.020 1.10 – 2.96 
Protective factors 
Urine WBC >10 cells/hpf  0.11 0.010 0.020 – 0.59 
Presence of urinary leukocytes  0.24 <0.001 0.11 – 0.53 
Recurrent or persistent SABU 0.26 0.002 0.11 – 0.61 
Nursing home resident 0.31 0.002 0.15 – 0.65 
Hpf = high-power field 
* Adjusted for diabetes, the presence of a urinary catheter, pure S. aureus culture, gender,  
   recurrent or persistent SABU and nursing home resident 
- Calibration (Pseudo R2)=0.08, discrimination (area under RoC curve)= 0.73** 
**Calibration of the final model was assessed using the Hosmer-Lemeshow goodness of  
    fit test and discrimination was assessed using the area under the receiver operator  
    curve.  
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Being a nursing home resident was associated with less risk of SAB. Unlike the data 
presented in Table 4 of the entire cohort, a recent urinary procedure was not associated 
with SAB in outpatient settings and dementia and age >65 was no longer statistically 
significant. This is likely due to a decrease in statistical power as a result of lower SAB 
rates in our study’s outpatients. 
 
Understanding SABU in Individuals with or without a Urinary Catheter 
There were 475 (18.7%) SABU individuals who had a urinary catheter at the time of 
urine collection. SAB occurred in 37 (7.8%) of catheterized individuals. Risk factors for  
SAB in this population revealed similar results as the overall SABU population (Table 7). 
Immunosuppression became a significant risk factor among catheterized individuals, 
though its confidence interval is very wide. In terms of protective factors, dementia was 
lost but nursing home resident became statistically significant. In individuals without a 
urinary catheter, SAB occurred in 138/2065 (6.7%) of individuals and the results of 
multivariate analysis are also similar to those of the overall population (Table 8). 
Interestingly MRSA became a statistically significant protective factor for SAB among 
non-catheterized SABU individuals.  
 
Systematic Review 
A systematic review and meta-analysis was conducted to determine whether urinary 
catheters in SABU individuals increases the risk for developing SAB.  
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Table 7      Multivariate logistic regression analysis of risk factors for SAB in SABU  
                   individuals who do have a urinary catheter (N=37/475). 
 
Predictor Odds ratio*  Adjusted  
p-value 
OR 95%  CI 
Risk factors 
Urinary procedure 12.28 <0.001 3.39 – 44.4 
Immunosuppressed 10.86 0.013 1.6 – 72.0 
Presence of immature neutrophils   5.44 0.002 1.8 – 16.2 
Serum platelets <120   5.12 0.008 1.54 – 17.1 
Protective factors 
Presence of urine leukocytes  0.17 0.012 0.04 – 0.68 
Nursing home resident 0.33 0.009 0.15 – 0.76 
Age>65 0.35 0.006 0.16 – 0.74 
Presence of urine nitrites  0.42 0.007 0.23 – 0.79 
*Adjusted for age >65 years, urinary procedure, nursing home resident and immunosuppression. 
- Calibration (Pseudo R2)=0.12, discrimination (area under RoC curve)= 0.74**. 
**Calibration of the final model was assessed using the Hosmer-Lemeshow goodness of fit tes t and 
discrimination was assessed using the area under the receiver operator curve.  
 
 
 
 
Table 8       Multivariate logistic regression analysis of risk factors for SAB in SABU  
                    individuals who do not have a urinary catheter (N=138/2065). 
 
Predictor Odds ratio* Adjusted p-
value 
OR 95%  CI 
Risk factors 
Presence of immature neutrophils   8.51 <0.001 4.70 – 15.40 
Serum WBC >15 x 109/L 5.46 <0.001 3.02 – 9.87 
Serum platelets <150 x 109/L 5.29 <0.001 2.67 – 10.48 
Inpatient 4.18 <0.001 2.87 – 6.10 
Males 2.55 <0.001 1.72 – 3.79 
Protective factors 
Presence of urine leukocytes  0.35 0.001 0.19 – 0.66 
Urine WBC >10 cells/hpf 0.35 0.039 0.13 – 0.95 
Recurrent or persistent SABU 0.37 0.006 0.18 – 0.75 
Presence of urine nitrite 0.42 0.007 0.23 – 0.79 
Age >65 0.49 <0.001 0.34 – 0.71 
MRSA  0.59 0.038 0.35 – 0.97 
WBC: white blood cells. 
Hpf: high-power field. 
*Adjusted for inpatient status, gender, recurrent or persistent SABU, age>65 and MRSA bacteriuria. 
- Calibration (Pseudo R2)=0.11, discrimination (area under RoC curve)= 0.75**. 
**Calibration of the final model was assessed using the Hosmer-Lemeshow goodness of fit test and 
discrimination was assessed using the area under the receiver operator curve.  
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The search strategy yielded 461 abstracts, of which 431 were excluded for not meeting 
inclusion/exclusion criteria (Figure 8). Subsequently, 30 papers were included for full text 
review, of which 9 papers met inclusion criteria for the systematic review.23-26,29,35,37,54,55 
 
Characteristics of SABU individuals from the 9 included studies are provided in Table 9. 
All studies were retrospective cohort studies and 8 out of 9 were conducted in a single 
center. Studies varied widely in terms of geographic location, individual characteristics 
and outcomes. Many studies occurred in veteran hospitals within the United States of 
America (USA).23,24,29 As a result, the vast majority of SABU individuals were male. 
SABU individuals were an average age of 66 years among studies. The presence of 
urinary catheters was high across studies and varied widely (23.9% – 82.0%). MRSA 
prevalence also varied widely across studies which is most likely due to differences in the 
time and location of study, with higher MRSA prevalence occurring among more recent 
American studies. The three studies that reported mixed vs pure growth of S. aureus in 
urine culture found that most cultures were of mixed growth (52.0% - 73.8%). Outcome 
definitions (SAB and death) varied between studies. For instance, some studies measured 
in hospital mortality37,54 while others measured mortality from two weeks to one year 
after SABU.23,24,26,29,37 Some studies excluded SAB due to known invasive S. aureus 
infection while others examined SAB within 72 hours or up to one year (Table 9).  
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*Other sources include conference proceedings from the Annual Meetings of the Infectious Diseases 
Society of America and references of relevant articles. 
 
Figure 8        Search strategy results using preferred reporting items for systematic  
                       reviews and meta-analysis (PRISMA) flow diagram.64 
 
 
 
 
Additional articles identified 
through other sources* 
(n = 3) 
Articles after duplicates removed 
(n = 461) 
Articles screened 
(n = 461) 
Articles excluded 
(n = 431) 
Full-text articles 
assessed for 
eligibility 
(n = 30) 
21 Full-text articles excluded 
 
1. Examined SABU in SAB only  
(n = 11) 
 
2. Review (n = 3) 
 
3. Case reports/series (n = 5) 
 
4. Did not distinguish SABU from 
other urinary pathogens 
(n = 1) 
 
5.  Did not report S. aureus 
Studies included in 
qualitative synthesis 
(n = 9) 
Articles identified through 
database searching 
(n = 513) 
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Table 9        Characteristics of studies included in systematic review. 
 
 
 Reller 
56 
Reyes 
38 
Arpi
26 Bermejo36 Demuth 
30 
Mohajer
25 
Muder
24 
Saidel-
O des
27 
Sheth
55 
Publication year 2004 2010 1984 2012 1979 2013 2006 2009 1997 
Geographic location USA USA Denmark Argentina USA USA USA Israel USA 
Sample size 138 149 132‡ 43 109 326 102 120 45 
SAB (%) 39.1 28.2* 8.3† 48.8 14.7 8.6• 13^ 12.0 11.1°° 
Invasive S . aureus 
disease without SAB 
- - - - 2.4 4.6 7.8 - 0.8 
MRSA (%) - 70 3.0 48.8  48.2 86 11.7 - 
Average age - 65 73 68.7 63.3 66.2 72.8 56 - 
Urinary Catheter (%) - 54 62.9 58.1 23.9 42.9 82.0 41.0 - 
Male (%) - - 81 58.1 98 94.5 100 57 - 
Pure S . aureus culture 
(%) 
- 48 35 - - 39.0 - - 26.2 
Colony count >108 
CFU/L (%) 
- 42 - - - - - - - 
Recent urinary 
procedure (%) 
- - 9.2 - - - 7 - - 
Nosocomial SABU 
(%) 
- - 81 65.1 55 57.7 - 30 - 
Recurrent or 
persistent SABU (%) 
- 20 - - - 17.5§ 58∆ - - 
Symptomatic UTI (%) 33 33 46/116 
(40%) 
- 28/69 
(40%) 
31.9 15.7 20 - 
Pyuria - - 78/99 
(79%) 
- 71 77.2 - 67.5 - 
Nursing home 
resident (%) 
- - - -  - 70 6.6 - 
Diabetes (%) - - - 25.6 18.0 39.6 42 30 - 
Death (%) - 11** - 23.2° 15.6Ω 23.6§§ 12.7∆∆ 12.5∆∆ 13.3§§ 
* 14.8% had SAB concurrently and 13.4% developed SAB within 1 year. 
**Death during hospitalization. 
‡ Excluded mixed cultures. 
† excluded SAB due to known invasive S. aureus infection. 
∆SABU after >2 months of initial SABU. 
^An additional 8/102 (7.8%) had SAB up to 12 months after initial SABU. 
∆∆Death within 30 days. 
°Definition of death unknown. 
°°An additional 4.4% developed invasive S. aureus disease 4 months after SABU. 
§§Death within one year. 
§ definition unknown. 
•An additional 4.0% developed SAB within 12 months of initial SABU. 
ΩDeath within two weeks of SABU. 
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Assessment of bias using the Newcastle-Ottawa quality assessment scale for cohort 
studies yielded similar results across studies (Table 10). Selection of participants was at 
low risk for all studies except for Arpi et al which excluded individuals who developed 
SAB due to known invasive S. aureus infections.25 We analyzed various exposures but all 
were felt to be low risk for bias. Measurement of outcomes and reported results and 
similarity of controls were also all at low risk for bias. Missing data and appropriate 
statistical analysis provided the highest risk of bias in included studies. As seen in Table 
10, data related to length of follow up of individuals were not consistent across studies. 
Several studies did not clarify duration of follow up25,29,55 and two studies had inadequate 
duration of follow up for outcome measurement (72 hours or less from SABU).26,35 The  
other studies examined SAB within 4 months to 1 year of SABU which was felt to be 
adequate. In terms of confounders, only one study clearly stated their use of statistical 
analyses for controlling potential confounders.24 All other studies were at high risk for 
bias due to failure to control for confounders. This caused most studies to be labeled as 
high risk for bias in the overall result, since controlling for confounders is one of the most 
critical factors in achieving good internal validity within retrospective studies.  
 
Unfortunately, all identified studies had poor external validity due to low sample sizes 
and studying SABU in very select populations. For example, the combined sample size of 
all studies was 1164, which represents only 46% of our study’s sample size. Furthermore, 
most studies were conducted in single center hospitals, with many occurring in veteran 
hospitals that have high populations of elderly men. Only one study included a second 
center but it had a very small sample size (18 SABU cases).  
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Table 10       Risk of bias assessment for included studies, based on the Newcastle-  
                      Ottawa quality assessment scale for cohort studies       
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Meta-Analysis 
Characteristics used in the meta-analysis are included in Table 11. Only studies that 
provided separate characteristics between SABU and SABU + SAB individuals were 
included.23-26,35 Our study was also included in the meta-analysis. Overall, there is a wide 
variation between characteristics among studies and many studies had missing data. 
Characteristics were combined using forest plots (see Figure 9 – 16). There was 
significant heterogeneity among studies and therefore a random effects model was used.  
 
In our pooled results, the presence of MRSA bacteriuria, urinary catheters, urinary 
obstruction, symptomatic UTI, and pyuria trended towards lower risk of SAB for 
individuals with SABU. Male gender, inpatient status, and diabetes trended towards  
higher risk of SAB for those experiencing SABU. However, only the presence of diabetes 
was statistically significant in the pooled results (OR 1.63, CI 1.14 – 2.33). Our primary 
question for meta-analysis - whether the presence of a urinary catheter is associated with 
increased risk of SAB in individuals with SABU - demonstrated a pooled OR of 0.75 
(0.36 – 1.58) with significant heterogeneity among studies (I2 74.3%). Using a fixed 
effects model did not change the result for MRSA, urinary catheter, urinary obstruction or 
diabetes. However, it did cause the pooled OR results among male gender, inpatient 
status, symptomatic UTI, and pyuria to become statistically significant. This is due to 
reduced weighting of studies with small sample sizes, leading to larger studies (especially 
ours) to have a larger effect on the pooled OR.    
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Table 11        Study characteristics used in meta-analysis. 
 
 Arpi
26
 Bermejo
36
 Mohajer
25
 Muder
24
 Saidel-O des
27
 Stokes 
 SABU 
n=121 
SAB 
n=11 
SABU 
 n=22 
SAB 
n=21 
SABU 
n=270 
SAB* 
n=56 
SABU 
n=89 
SAB 
n=13 
SABU 
n=91 
SAB 
n=12 
SABU 
n=2365 
SAB  
n=175 
MRSA (%) - - 59.1 38.1 45.2 62.5 87.6 76.9 - - 23.6 17.1 
Urinary 
Catheter (%) 
62.8 63.4 81.2 19.0 43.7 39.3 49.4 76.9 30.7 16.7 18.5 21.1 
Male (%) - - 59.1 57.1 93.3 100 - - - - 51.3 69.7 
O bstruction 
(%) 
54.5 72.3 - - - - - - 26/90 
(28.9) 
1/11 
(9.1) 
- - 
Nosocomial 
SABU (%) 
- - 72.3 57.1 51.1 89.3 - - 30.7 33.3 27.3 56.0 
UTI 
symptoms 
(%) 
43/11
6 
(37.1) 
3/9 
(33.3) 
- - 35.9 12.5 29.2 53.8 17/85 
(20.0
%) 
1/10 
(10%) 
- - 
Pyuria (%) 70/99 
(70.1) 
8 
(72.3) 
- - - - - - 47/69 
(68.1) 
6/9 
(66.7) 
293/3
32 
(88.3) 
14/24  
(58.3) 
Diabetes (%) - - - - 39.6 42.9 40.4 53.8 - - 10.6 18.9 
*Includes individuals with non-bacteremic, invasive S. aureus disease (n=15). 
 
 
 
 
Figure 9        Forest plot of odds ratios of development of SAB in individuals with  
                       urinary catheters. 
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Figure 10       Forest plot of odds ratios of development of SAB in individuals with     
                       MRSA bacteriuria. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Figure 11        Forest plot of odds ratios of development of SAB in male individuals. 
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Figure 12      Forest plot of odds ratios of development of SAB in SABU individuals   
                       with urinary obstruction. 
 
 
 
 
Figure 13       Forest plot of odds ratios of development of SAB in SABU individuals  
                       who are hospitalized. 
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Figure 14       Forest plot of odds ratios of development of SAB in SABU individuals  
                       who have symptoms of urinary tract infection. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15      Forest plot of odds ratios of development of SAB in SABU individuals   
                       who have pyuria. 
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Figure 16      Forest plot of odds ratios of development of SAB in SABU individuals  
                       who have diabetes. 
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Assessment for publication bias was conducted based on the association of urinary 
catheters and SABU + SAB. Begg and Mazumdar’s rank correlation test for asymmetry 
was 0.707 suggesting that there is no publication bias. Visually, the associated funnel plot 
does not appear symmetrical which suggests that publication bias may be present (Figure 
17). The funnel plot also demonstrates an outlier, which corresponds to Muder et al.23 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17        Assessment of publication bias using funnel plot with pseudo 95%  
                        confidence limits among studies examining the association of urinary  
                        catheterization and SAB in individuals with SABU 
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DISCUSSION 
 
 
Epidemiology of SABU 
We have discovered that SABU is a rare occurrence, representing a mere 0.4% of all 
positive urine cultures in our region over 4 years. Furthermore, SABU cases have been 
decreasing annually in the CHZ while SABU + SAB rates remain constant. In discussion 
with the medical microbiologists and senior microbiology technicians in Calgary’s 
centralized laboratory, no significant changes to the collection, transportation, processing 
or reporting of urinary specimens that might have impacted these results occurred during 
the study period. Part of the decrease in SABU prevalence may be related to the 
decreasing prevalence of urinary catheters observed in our study. Decreased catheter use 
may be the result of local, national and international education and awareness campaigns 
related to the inappropriate use and potential harm of urinary catheters that have been 
ongoing for at least the last two decades.66 These campaigns exist because urinary 
catheters are often unnecessary, alternatives such as condom catheters exist and major 
complications including urinary tract infection and death can result.67,68 It is also 
economically beneficial to reduce inappropriate catheter use since complications from 
urinary catheters can cost healthcare systems millions of dollars. In the USA, for 
example, these complications are projected to cost over $450 million per year.69  
 
Compared with the CHZ population, SABU occurred disproportionally in the geriatric 
male population (median age 74) with a high number of comorbidities, particularly 
diabetes (10.6%) and dementia (6.7%). This correlates with current published literature 
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that showed SABU occurred more commonly among older age groups (average age 66 – 
73 years),23-26,30,33,37 in men,25 and individuals with multiple comorbidities.23-26,33,34,37 
Specific comorbidities such as urological disease and diabetes were also frequently 
observed within our study, though these comorbidities were not associated with increased 
risk for SAB with the exception of diabetes in outpatients with SABU. In most studies, 
diabetes was generally higher among SABU individuals (18.0% – 42.0%) compared to 
our study individuals (21.8%). Poor external validity associated with conducting studies 
at single center hospitals in selected individual populations (i.e. veterans) could account 
for the higher diabetes prevalence detected in the literature. However, our study may have 
lower comorbidity rates due to incomplete data - described in detail under study 
limitations. 
 
In our study, most S. aureus urine cultures were of pure growth. This is in contrast to four 
other studies which found most S. aureus urine cultures had mixed growth (52.0% - 
73.8%).24,25,37,54 No other studies were found that commented on microorganisms seen in 
mixed SABU cultures. In our study, Enterococcus spp. was the most common 
microorganism detected in mixed SABU cultures. Since S. aureus and Enterococcus can 
be part of normal perirectal flora, this finding would suggest that many mixed SABU 
cultures were due to contamination during sample collection. While the presence of pure 
S. aureus urine culture is associated with SAB in our study, the association is not strong 
(OR 1.6). This leads us to conclude that S. aureus present in the urine should not – in-
and-of-itself – be a cause for concern by care providers regardless of purity.  
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Association of Death Among SABU individuals 
Risk factors associated with death among SABU individuals in our study, based on 
multivariate logistic regression, represented common risk factors in any population, such 
as inpatient status; increasing age; cancer; cardiovascular diseases such as congestive 
heart failure; and respiratory diseases such as chronic obstructive pulmonary disease. 
However, we also discovered that SABU detected 48 hours or more before SAB was 
independently associated with higher risk of death and had a much higher probability of 
death than individuals who had concurrent SAB + SABU. This highlights the importance 
of quickly identifying SAB when SABU is detected and may suggest a role for the 
microbiology laboratory to communicate the urgency of these findings to clinicians. On 
the other hand, pyuria and recurrent or persistent SABU was associated with less risk of 
death and is possibly related to the inverse association of these variables with SAB and 
other deeper-seated S. aureus infections.  
 
Association of SAB in SABU 
While SABU in the context of SAB is uncommon, it represents an entirely different 
disease entity and every effort is required to distinguish it. From our population data, we 
discovered that individuals with SABU + SAB have more comorbidities than the general 
population, but less comorbidities than SABU individuals. This can be explained by 
certain populations who are at high risk for SAB but unlikely to have isolated SABU 
otherwise. For example, intravenous drug users will almost certainly have SAB when 
SABU is detected and are often young in age with few comorbidities.  
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Epidemiologic risk factors associated with SAB in individuals with SABU, in our study, 
were male gender, inpatient status, pure S. aureus culture, urinary procedure and systemic 
signs of infection (leukocytosis, thrombocytopenia and presence of immature 
neutrophils). Some studies were able to associate inpatient status and male gender with 
deeper-seated S. aureus infection or SAB.24,55 Other studies were not able to demonstrate 
a similar relationship; though many were conducted predominately among inpatients 
and/or males. Diabetes, liver cirrhosis, malignancy, diabetes, and immunosuppression 
were all risk factors for SAB on univariate analysis but not when imputed into the 
multivariate regression model.  
 
Our findings on urinary procedures and its association with SABU + SAB contradict 
current literature that has previously suggested no association or a reduced association of 
urinary procedures and risk of SABU + SAB.35,55 However, we feel our results correlate 
better with the pathophysiology behind urinary tract procedure complications. For 
instance, any manipulation of human tissue can increase the risk of bacteremia, and 
urinary procedures such as cystoscopy or percutaneous nephrostomy tube placement are 
no exception.70-74 During nephrostomy tube placement, endogenous skin flora such as S. 
aureus may become exposed to the disrupted tissue. Subsequently, S. aureus may 
propagate its infection within the underlying skin, the deeper tissue (i.e. ureter) and 
eventually the bloodstream leading to SABU + SAB. During cystoscopy, the cystoscope 
may become contaminated with S. aureus during initial insertion from S. aureus 
colonization of the urethra and surrounding area. S. aureus contaminating the cystoscopy 
device can then invade and infect underlying tissue that is disrupted during the procedure, 
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leading to SABU + SAB. While it is possible that these procedures could inoculate the 
bladder with S. aureus without causing bacteremia, we would think that the inflamed and 
damaged uroepithelial tissue post procedure would make these SABU individuals more 
susceptible to bacteremia compared to other SABU individuals.  
 
Factors that were uncommon in SABU individuals with concurrent SAB included 
dementia, recurrent or persistent SABU, age ≥65 years and the presence of pyuria and 
urine nitrites. The presence of pyuria correlates with another study that demonstrated 
decreased risk of SAB in individuals with pyuria.55 If S. aureus bacteriuria in the context 
of SAB is a result of hematogenous seeding, perhaps the urinary tract would have less 
opportunity to mount a local inflammatory response and therefore less likely to have 
pyuria.75 Compared to Staphylococcus saprophyticus and other urinary pathogens, S. 
aureus has lower affinity for uroepithelial cells and therefore SABU secondary to 
hematogenous seeding may quickly be eliminated from the bladder before significant 
local reaction.76 The corollary would be that SABU isolated to the urinary tract would 
persist for longer periods of time thereby generating inflammation, and nitrite (S. aureus 
has a nitrite reductase but it takes 4 to 6 hours to occur within the bladder).75,76 Moreover, 
age ≥65 years and recurrent or persistent SABU negatively associate with SAB in SABU. 
This is supported by nursing home residents being a protective factor on univariate 
analysis as it correlates with established literature demonstrating SABU among elderly 
nursing home residents with asymptomatic bacteriuria (many of whom have 
dementia).77,78 Asymptomatic bacteriuria among nursing home residents often is not 
associated with a UTI or systemic infection and this may apply to SABU as well, so long 
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as a deeper seated infection has been ruled out.79 Importantly, this information can be 
used by clinicians to deprioritize individuals at perceived lower risk for immediate 
investigations.  
 
Association of SAB in Outpatients with SABU 
We specifically examined the association of SAB in outpatients with SABU as they 
represent a clinical challenge compared to inpatients. Investigation and monitoring for 
SAB can be easily achieved amongst hospitalized individuals, outpatients must be 
contacted and referred immediately to the laboratory for repeat testing– or perhaps even 
the emergency room for investigations. In our study, risk factors for SAB in outpatients 
included males, serum biochemical markers of inflammation, the presence of a catheter, 
pure S. aureus culture and diabetes. Why the presence of a urinary catheter becomes a 
risk factor for SAB in SABU as an outpatient only is unclear. Perhaps it is because our 
study was not able to distinguish individuals who had a long-term, indwelling urinary 
catheter versus individuals who had a temporary catheter or in/out catheterization. In this 
regard, the presence of a urinary catheter in outpatient SABU individuals may better 
represent people who have chronic indwelling urinary catheters which are at higher risk 
of S. aureus acquisition and, perhaps, subsequent complications such as ascending urinary 
tract infection.33 Furthermore, the presence of pure S. aureus among catheterized SABU 
individuals may represent infection as opposed to colonization or poor sampling which 
would be associated with other microorganisms such as Enterococcus spp.  
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Association of SAB in SABU Individuals with or without the Presence of a  
           Urinary Catheter 
A sensitivity analysis was done on individuals with or without a urinary catheter since 
SABU is often associated with urinary catheter use. In our study, we found that the 
majority (81.3%) of SABU individuals did not have a catheter at the time of urine culture 
collection. This counters findings from many hospital-based studies that reported catheter 
use among the majority of their SABU individuals.23,25,26,35,37 Furthermore, the 
development of SAB in our SABU cohort with or without a urinary catheter was roughly 
equal between the groups at 7.8% and 6.7%, respectively. Risk factors associated with 
SAB occurrence in SABU individuals without a urinary catheter was approximately the 
same as the overall results, with the exception that urinary procedure and pure S. aureus 
growth was not associated with increased risk of SAB. The lack of pure S. aureus growth 
as a risk factor for SAB in individuals with SABU implies that the presence alone of S. 
aureus in the urine should be considered a marker for systemic infection in individuals 
without a urinary catheter, regardless of other bacteria present. Furthermore, the presence 
of dementia was not associated with decreased risk of SAB but the presence of MRSA 
was. This is in contrast with Mohajer et al who demonstrated increased risk of SAB in 
individuals with MRSA bacteriuria.24 Given that Mohajer et al’s study was in a single 
hospital setting, the presence of MRSA may be due to confounders related to MRSA 
nosocomial acquisition and S. aureus bacteremia, such as critically ill individuals with 
central venous lines in the intensive care unit.24  
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In catheterized individuals with SABU, there are several interesting changes to the risk 
factors associated with SAB. For instance, a recent urinary procedure becomes the most 
significant risk factor for developing SAB among catheterized individuals. This is 
interesting, since recent urinary procedures for non-catheterized individuals is not a risk 
factor for SAB, indicating that many SAB + SABU cases post urinary procedure occurred 
among catheterized individuals (despite urinary procedures among catheterized and non-
catheterized individuals being similar at 2.3% vs 2.5%, respectively). Since SABU is 
more common among catheterized individuals, it is likely that the increased risk of SABU 
+ SAB in these individuals is simply due to an increased likelihood that S. aureus is 
present in the urinary tract prior to a urinary procedure in these individuals (and 
subsequently more likely for invasive S. aureus infection to occur).  
 
Invasive S. aureus Infection without SAB 
Individuals with SABU and invasive infections without documented SAB represented a 
small proportion in our study (0.8%) – although our cohort represents the largest 
published to date. This is in contrast to the 4.6% of SABU and invasive S. aureus 
infections without SAB in the only study that assessed for it.24 This may be secondary to 
our study having strict microbiological criteria for deeper-seated S. aureus infection 
compared to Mohajer et al who used a combination of clinical, microbiological and 
radiographic data.24 In their study, the most common associated infection in individuals 
who had an invasive S. aureus infection without bacteremia over 12 months from SABU 
was pneumonia in 56.3% followed by osteomyelitis in 25.0%.24 In our study, surgical site 
infections post urological surgery was the most common (24%) followed by intra-
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abdominal/pelvic abscess (19%). These infections could cause SABU but not SAB due to 
their anatomical proximity to the kidneys that could lead to S. aureus seeding of the 
urinary tract without seeding into the blood. However, it is possible that many of these 
infections had transient S. aureus bacteremia that allowed for seeding of the urinary tract 
instead.  
 
Associated Infections of Invasive S. aureus Infection Complicating SABU,   
Regardless of SAB 
In both SAB and deeper-seated S. aureus infection, we (similar to others) detected a large 
proportion of SABU individuals with pyogenic spine/pelvic infection with the vast 
majority having lumbar discitis and epidural abscess.80 A recent meta-analysis also 
demonstrated an association of bone/joint infections as well as septic emboli among SAB 
individuals who were found to have SABU.56 Osteomyelitis due to Gram-negative urinary 
tract infections is well established, particularly in older individuals who have higher rates 
of bacteriuria,81 and is thought to be due to the connection of venous networks between 
the pelvic/spine area and bladder.82 These results highlight that mere blood cultures may 
be inadequate in some cases to exclude deeper-seated disease when SABU is first 
identified, particularly in excluding vertebral osteomyelitis which was found to be 
common among SABU individuals with negative blood cultures but invasive S. aureus 
disease. This highlights that a thorough history and physical examination for potential 
occult focuses of infection – and especially vertebral osteomyelitis - should be sought 
whenever an individual is found to have SABU.  
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From the results of our study we believe S. aureus bacteriuria with S. aureus bacteremia 
is a result of one of three major processes. One is seeding of S. aureus from spinal 
osteomyelitis secondary to Batson’s plexus. Second, S. aureus urinary tract infection 
ascending into the urinary tract and then the blood, resulting in both SAB and SABU 
(although we caution readers that this likely represents a minority of cases). The third is 
disseminated S. aureus bacteremia seeding into the urinary tract, as evidenced in animal 
studies injected with S. aureus,83 that resulted in renal microabsccess; although one study 
failed to find autopsy evidence of a renal abscess among SABU patients29 and only 2/6 
(33.3%) of SABU patients were found to have a renal abscess in another study.84 In our 
study, we could find no radiologic evidence of renal abscesses in our individuals with 
SABU + SAB who had abdominal imaging. 
 
Systematic Review and Meta-Analysis 
From our systematic review, we concluded that there was a paucity of literature on the 
association of SAB among SABU individuals. Only nine studies were identified when 
searching multiple databases, including conference abstracts. When examining the 
included studies, large variation and heterogeneity was detected. Internal validity in most 
studies, with the exception of Mohajer et al, was at high risk of bias due to the lack of 
controlling for confounders which is a significant limitation in retrospective cohort 
studies. Moreover, external validity was poor among studies, with most having very small 
sample sizes and most being conducted in single centers (often in veteran hospitals). 
Overall, we feel these studies were at high risk of bias and were not generalizable to 
Canadian hospitals or outpatient settings. 
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The results of our meta-analysis indicated that the presence of a urinary catheter among 
SABU individuals is not associated with the development of SAB. However, we did 
determine that diabetes was associated with the development of SAB when pooling odds 
ratios among studies. Increased risk of SAB in diabetic individuals is not surprising, since 
diabetic individuals (especially poorly controlled diabetics) are at increased risk of many 
infections, including UTI.85 However, caution is made that the results from our meta-
analysis of retrospective cohort studies could not control for confounding which is a 
significant limitation.  
 
Strengths and Limitations 
Our study is the largest investigating the association between S. aureus bacteriuria and S. 
aureus bacteremia and/or deeper-seated S. aureus infection. We were able to study SABU 
from a large, general Canadian population of over 1.4 million, providing strong external 
validity to our conclusions. Furthermore, we were able to determine the association of 
SABU + SAB in outpatient settings, in which the decision to investigate underlying SAB 
can be challenging.   
 
Although a rigorous population-based design was utilized, there are study limitations 
warranting discussion. This study does not establish a causal relationship between SABU 
+ SAB and mortality. The observed mortality rates may have been influenced by other 
illnesses and co-morbidities. Our multiple logistic regression models were of low 
calibration, making the strength of our associations weaker.  Only cases of SABU 
associated with positive urine cultures were included in the study. Individuals with SABU 
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who did not have urine samples submitted for culture were not identifiable; as a result, the 
reported incidence of SABU is likely a conservative estimate. This limitation exists in all 
studies dependent on culture-proven infection. Although microbiologic data was collected 
prospectively, clinical data was retrospectively documented, and individuals were not 
assessed through the auspices of the study to determine the original infection source. We 
are unable to assess independent risk factors for SABU using logistic regression. We 
estimated the rates of underlying illnesses in the general population based on current 
disease prevalence registry data, but do not have individualized, linked data on all 1.4 
million residents. This limitation is nearly universal to all population-based study 
designs.86,87 There are also inherent limitations in using international classification of 
diseases (ICD)-9 codes for defining co-morbid illness.  
 
When collecting data, we were dependent upon electronic databases that may have 
missing data such as the full extent of an individual’s comorbidities. Data on individual 
comorbidities were only accessible if the individual had accessed one of Calgary’s acute 
care centers or specialty clinics. Some S. aureus bacteremia and S. aureus deeper seated 
infections may have been missed if they occurred before or after our 3 months cut off 
from SABU without a repeat positive urine culture for S. aureus. In addition, bias may 
have been created by studying bloodwork that was collected in only a portion of 
individuals. However, most would agree that our laboratory findings are biologically 
plausible and consistent with general knowledge about S. aureus bacteremia, and are 
supported by previous literature that demonstrated decreased SAB risk in the context of 
SABU with pyuria.55 
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Urinary catheterization, immunosuppression and death may have been underreported in 
our study. We could only confirm the presence of a urinary catheter if the urine culture 
specimen was taken from a catheter. Therefore, we were not able to determine if an 
individual with a mid-stream urine sample had a recent history of urinary catheterization. 
People on immunosuppression medication (e.g. chemotherapy, immunologics, etc) could 
not be captured with the database except for the ICD-9 code “chronic steroid use” which 
would not capture individuals who are on steroids for short or moderate durations. 
Furthermore, since death was defined as death occurring within the hospital, individuals 
who died outside the hospital would not have been detected.  
 
Another limitation of our study is the inability to determine whether SABU represented 
asymptomatic bacteriuria versus symptomatic cystitis. In studies with strict definitions for 
symptomatic UTI, approximately 30% of individuals with SABU were symptomatic.23,24 
In the largest study, individuals with SAB were less likely to have urinary symptoms.24 
Indeed, in a study examining E. coli bacteriuria in a tertiary hospital, 61.7% were 
symptomatic.88 This finding may be related to our association of pyuria with isolated 
SABU, although we are unable to draw any conclusions given the retrospective nature of 
our study. Further research on isolated SABU is required to help determine the true nature 
of its symptomatology, especially in outpatient settings where a paucity of SABU 
research exists.  
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Future Directions 
Our next aim is to validate a risk score that clinicians can use at the bedside to help 
determine an individual’s risk of SAB when SABU is identified. To create the risk score, 
regression coefficients from our multivariate regression model will be used. We can then 
validate the risk score by applying it to a new subset of SABU individuals within the 
Calgary Health Zone, such as those from different years (e.g. 2014 – 2017). Our objective 
is to ultimately help clinicians determine their patient’s risk of developing SAB when 
SABU is detected. Similar to other risk scores, such as Wells’ criteria for pulmonary 
embolism, a score can be calculated at the point of care (e.g. via a user friendly 
smartphone app) and, based on the score, the probability of SAB will be calculated (e.g. a 
score of five correlates with a 75% probability of SAB developing within three months). 
This score can help prompt clinicians to consider further testing, such as blood cultures, 
in high risk individuals. 
 
There are other smaller projects related to the symptomatology and treatment of SABU 
that we are interested in carrying forward. To date, the relationship between SABU, UTI 
symptoms, and treatment are still not fully addressed. We can help answer these questions 
by pursuing chart reviews on a subset of individuals included in our current study. Charts 
will be reviewed to determine if the individual was symptomatic around the time of urine 
culture collection, had blood cultures drawn to assess for SAB, and to determine if the 
individual was given antimicrobial treatment for SABU. Using these data and data 
already obtained from our study, we can add to the literature by determining how many 
individuals with SABU have urinary tract symptoms and what factors might increase their 
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likelihood of having symptoms (e.g. presence of nitrites, presence of a urinary catheter, 
pure S. aureus culture, high S. aureus colony count, etc). We can also determine which 
individuals were treated and, if not, how many developed complications (e.g. SAB) when 
not treated. Most importantly, we can see whether we can apply the rule of 
“asymptomatic bacteriuria” to SABU, meaning that if S. aureus is discovered in an 
individual without urinary symptoms that the individual does not require treatment 
(though, of course, invasive S. aureus should be ruled out before foregoing treatment).89 
 
Furthermore, as a quality improvement component, we can use blood culture data to help 
us determine how many individuals with SABU have had blood cultures taken. While 
most individuals with SABU do not have SAB, we do not currently have an easy way to 
exclude this. As such, until further tools are available to clinicians, we believe all 
individuals with SABU should have a blood culture done to rule out SAB. Our 
hypothesis, however, is that few SABU individuals from the Calgary Health Zone are 
getting blood cultures drawn when SABU is detected. If this is the case, we can use our 
data to help justify quality improvement initiatives that aim to improve blood culture 
collection among these individuals, such as providing a comment on positive S. aureus 
urine culture results that state, “blood cultures are suggested to help rule out systemic S. 
aureus infections.”  
 
 
 
 
58 
 
Conclusion 
SABU generally represents one of two very different disease processes; a marker of a 
potentially life threatening invasive infection or much more commonly isolated cystitis / 
asymptomatic bacteriuria. In the largest study to date examining SABU, we have 
discovered specific risk factors that can help clinicians distinguish between these 
scenarios. Based on an individual’s risk factors and the clinician’s judgment, 
investigation for SAB or deeper-seated S. aureus infections such as vertebral 
osteomyelitis should be sought if clinically suspected, especially since a delay in SAB 
detection is associated with increased mortality. Going forward, we recommend that 
clinical microbiology laboratories report in individuals with SABU that “S. aureus 
bacteriuria may be associated with severe systemic disease such as bacteremia - 
particularly in hospitalized patients and/or those with systemic symptoms. Clinical 
correlation is advised.” 
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APPENDICES 
 
Appendix A: Search strategy (PubMed) 
Database: PubMed 
 
Search strategy: 
1. Staphylococcus aureus [MeSH Terms] 
2. Staphylococcus aureus 
3. S. aureus 
4. #1 OR #2 OR #3 
5. urinary tract infection [MeSH Terms] 
6. Urinary tract infection 
7. UTI 
8. Bacteriuria [MeSH Terms] 
9. Bacteriuria 
10. #5 OR #6 OR #7 OR #8 OR #9 
11. Bacteremia [MeSH Terms] 
12. Bloodstream infection 
13. BSI 
14. #11 OR #12 OR #13 
15. #4 AND #10 AND #14 
 
 
 
 
 
